Daily Respiratory Research Analysis
Analyzed 44 papers and selected 3 impactful papers.
Summary
Three papers stood out today: a large target trial emulation shows RSV vaccination reduces infection, hospitalization, and all-cause mortality in solid organ transplant recipients; a multinational BOLD cohort analysis confirms forced vital capacity is a robust prognostic marker for survival across regions; and a randomized physiologic study demonstrates that inhaled nitric oxide improves ventilation-perfusion matching in moderate-to-severe ARDS using EIT.
Research Themes
- Vaccine effectiveness in high-risk respiratory populations
- Lung function metrics as global prognostic tools
- Physiologic personalization of ARDS therapy with EIT
Selected Articles
1. Effectiveness of Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients in the United States.
In a nationwide EHR-based target trial emulation of 63,108 SOTRs ≥60 years, RSV vaccination was associated with lower RSV infection (HR 0.70), RSV-related hospitalization (HR 0.61), and all-cause mortality (HR 0.45), but not ICU admission or intubation. Findings were robust across sensitivity and subgroup analyses.
Impact: Provides the first large-scale real-world effectiveness data for RSV vaccination in immunosuppressed transplant recipients, directly informing vaccination policy for a high-risk group.
Clinical Implications: Transplant programs should proactively recommend RSV vaccination for eligible SOTRs ≥60 years and integrate reminders into post-transplant care pathways, anticipating reductions in RSV-related morbidity and mortality.
Key Findings
- RSV vaccination reduced RSV infection risk (HR 0.70, 95% CI 0.56–0.88).
- RSV vaccination reduced RSV-related hospitalization (HR 0.61, 95% CI 0.43–0.86).
- RSV vaccination reduced all-cause mortality (HR 0.45, 95% CI 0.41–0.50).
- No significant effect on ICU admission or intubation; results consistent across sensitivity and subgroup analyses.
Methodological Strengths
- Target trial emulation with risk-set matching to address immortal time and timing biases.
- Large, multicenter EHR dataset enabling robust multivariable adjustment and subgroup analyses.
Limitations
- Observational design with potential residual confounding and misclassification inherent to EHR data.
- Generalizability limited to SOTRs ≥60 years and specific health systems; vaccine product/schedule details not fully specified.
Future Directions: Prospective studies to optimize timing post-transplant, evaluate durability and booster strategies, and assess effectiveness in younger SOTRs and by vaccine platform.
Respiratory syncytial virus (RSV) is associated with high morbidity in solid organ transplant recipients (SOTRs) and the effectiveness of the RSV vaccine in this population is unknown. We sought to assess the real-world performance of the RSV vaccine in SOTRs through a retrospective cohort study emulating a target trial using Epic Cosmos. We identified SOTRs with post-transplant follow-up between 10/01/2023 and 03/31/2025 and were ≥60 years old. Risk-set matching was used to account for the timing of vacc
2. A cohort study of forced vital capacity, airway obstruction, and survival in the multinational Burden of Obstructive Lung Disease study.
Across 9,927 participants (1,120 deaths; mean follow-up 8.7 years), higher baseline post-bronchodilator FVC was more strongly associated with lower mortality than FEV1/FVC after mutual adjustment. Each SD higher FVC reduced mortality by 44% in men and 28% in women, with low probability of true regional differences.
Impact: Clarifies that FVC is a robust prognostic marker across diverse regions, challenging the need for regional prognostic adjustments and informing global risk stratification.
Clinical Implications: Use FVC, adjusted for age, sex, and height, as a primary prognostic indicator in global settings; avoid regional prognostic adjustments that downplay risk in populations with lower average FVC.
Key Findings
- Higher baseline post-bronchodilator FVC was inversely associated with mortality across 16 international sites.
- After mutual adjustment, FVC had a stronger mortality association than FEV1/FVC (44% lower mortality per SD in men; 28% in women).
- Meta-analysis suggested a low probability of true regional differences in associations.
- Findings argue against regional adjustments to lung function standards for prognostic assessment.
Methodological Strengths
- Large, multinational cohort with long follow-up (mean 8.7 years) and site-specific Cox models.
- Standardized spirometry with post-bronchodilator values and meta-analytic synthesis across sites.
Limitations
- Observational design susceptible to residual confounding; lung function measured at baseline only.
- Site inclusion required ≥5 deaths, and mortality ascertainment could vary across settings.
Future Directions: Evaluate interventions targeting preservation of lung volumes and investigate causal pathways linking reduced FVC to mortality across diverse populations.
BACKGROUND: In the USA, higher forced vital capacity (FVC) is linked with longer survival, and FVC is associated with survival independently of ethnicity. The implications for the low FVC values in parts of Asia and Africa are unknown. METHODS: We used data from 16 sites of the multinational Burden of Obstructive Lung Disease (BOLD) study that completed follow-up of participants between 2019 and 2021 and reported at least five deaths between baseline and follow-up. We assessed the association of mort
3. Effects of inhaled nitric oxide on ventilation/perfusion mismatch assessed by electrical impedance tomography in intubated patients with moderate-to-severe ARDS: a prospective physiological study.
In a single-center RCT of 40 intubated ARDS patients, 24-hour iNO significantly improved V/Q matching versus control, reducing EIT-measured shunt and dead space (both P<0.001), with parallel improvements in oxygenation (higher PaO2/FiO2). The study provides mechanistic evidence for iNO’s physiologic benefits and supports EIT-guided personalization.
Impact: Delivers randomized, mechanism-focused evidence that iNO improves V/Q matching in ARDS using bedside EIT, advancing precision respiratory support strategies.
Clinical Implications: Consider short-term iNO as a rescue adjunct in moderate-to-severe ARDS when EIT demonstrates V/Q mismatch amenable to vasodilation; integrate EIT to identify responders and avoid futile exposure.
Key Findings
- iNO reduced EIT-derived shunt and dead space over 24 hours compared with control (between-group differences, P<0.001).
- Improvements in V/Q matching translated into better gas exchange with higher PaO2/FiO2.
- EIT provided real-time, noninvasive assessment to quantify iNO’s physiologic effects.
- Randomized design supports causal interpretation of iNO’s V/Q effects in ARDS.
Methodological Strengths
- Randomized controlled design with objective bedside EIT metrics of V/Q matching.
- Prospective protocolized 24-hour assessment linking physiology to gas exchange.
Limitations
- Single-center, small sample size limits generalizability and power for clinical outcomes.
- Retrospective trial registration and short (24 h) observation window without long-term endpoints.
Future Directions: Multicenter trials integrating EIT-guided selection to test iNO’s impact on patient-centered outcomes and to define responder phenotypes.
BACKGROUND: Inhaled nitric oxide (iNO) improves oxygenation in acute respiratory distress syndrome (ARDS), but its precise physiological effects on ventilation-perfusion (V/Q) matching and inflammation over 24 h remain to be fully elucidated. To determine the effect of iNO on V/Q matching, gas exchange, and systemic inflammatory response in mechanically ventilated patients with moderate-to-severe ARDS. METHODS: We conducted a prospective, single-center, randomized controlled trial in 40 mechanically